Heart failure hope for Novartis first-in-class neprilysin inhibitor
This article was originally published in Scrip
Novartis may be able to plug the gap in treatments for heart failure with preserved ejection fraction with its novel product LCZ696, based on positive effects on a surrogate marker in a Phase II trial presented this weekend at the European Society of Cardiology meeting in Munich.
You may also be interested in...
Entresto has narrowly failed to hit the primary endpoint in a Phase III trial in heart failure with preserved ejection fraction, a potentially lucrative indication with no approved treatments.
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.
Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.